Evidence map›Paper›PMID 24982195›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2014

Neurotrophin receptor TrkB promotes lung adenocarcinoma metastasis.

Kerstin W Sinkevicius, Christina Kriegel, Kelly J Bellaria, Jaewon Lee, Allison N Lau, Kristen T Leeman, Pengcheng Zhou, Alexander M Beede, Christine M Fillmore, Deborah Caswell and 9 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 87 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021
    Article
  20. How selecting best therapy for metastaticTranslational lung cancer research · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 1 country.

Kerstin W SinkeviciusStem Cell Program, Boston Children's Hospital, Boston MA 02115;Harvard Stem Cell Institute, Cambridge, MA 02138;Department of Genetics, Harvard Medical School, Boston, MA 02115;
Christina KriegelStem Cell Program, Boston Children's Hospital, Boston MA 02115;Harvard Stem Cell Institute, Cambridge, MA 02138;Department of Genetics, Harvard Medical School, Boston, MA 02115;
Kelly J BellariaStem Cell Program, Boston Children's Hospital, Boston MA 02115;Harvard Stem Cell Institute, Cambridge, MA 02138;Department of Genetics, Harvard Medical School, Boston, MA 02115;
Jaewon LeeDepartment of Cell Biology and The Paul F. Glenn Laboratories for the Biological Mechanisms of Aging, Harvard Medical School, Boston, MA 02115;
Allison N LauStem Cell Program, Boston Children's Hospital, Boston MA 02115;Harvard Stem Cell Institute, Cambridge, MA 02138;Department of Genetics, Harvard Medical School, Boston, MA 02115;
Kristen T LeemanDepartment of Pediatrics, Division of Newborn Medicine, Boston Children's Hospital Boston, Harvard Medical School, Boston, MA 02115;
Pengcheng ZhouDepartment of Pediatric Oncology and Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115;Department of Neurobiology, Harvard Medical School, Boston, MA 02115;
Alexander M BeedeStem Cell Program, Boston Children's Hospital, Boston MA 02115;Harvard Stem Cell Institute, Cambridge, MA 02138;Department of Genetics, Harvard Medical School, Boston, MA 02115;
Christine M FillmoreStem Cell Program, Boston Children's Hospital, Boston MA 02115;Harvard Stem Cell Institute, Cambridge, MA 02138;Department of Genetics, Harvard Medical School, Boston, MA 02115;
Deborah CaswellCancer Biology Program, Stanford University School of Medicine, Stanford, CA 94305;
Juliana BarriosStem Cell Program, Boston Children's Hospital, Boston MA 02115;Harvard Stem Cell Institute, Cambridge, MA 02138;Department of Genetics, Harvard Medical School, Boston, MA 02115;
Kwok-Kin WongDepartment of Medical Oncology and Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02115;Department of Medicine, Harvard Medical School, Boston, MA 02115;
Lynette M ShollDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115;
Thorsten M SchlaegerStem Cell Program, Boston Children's Hospital, Boston MA 02115;Harvard Stem Cell Institute, Cambridge, MA 02138;
Roderick T BronsonDana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA 02115; and.
Lucian R ChirieacDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115;
Monte M WinslowCancer Biology Program, Stanford University School of Medicine, Stanford, CA 94305;Department of Genetics and Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305.
Marcia C HaigisDepartment of Cell Biology and The Paul F. Glenn Laboratories for the Biological Mechanisms of Aging, Harvard Medical School, Boston, MA 02115;
Carla F KimStem Cell Program, Boston Children's Hospital, Boston MA 02115;Harvard Stem Cell Institute, Cambridge, MA 02138;Department of Genetics, Harvard Medical School, Boston, MA 02115; carla.kim@childrens.harvard.edu.
Harvard University · USBoston Children's Hospital · USHarvard Stem Cell Institute · USStanford University · USBoston Children's Museum · USDana-Farber Cancer Institute · USDana-Farber/Harvard Cancer Center · US

Funding

Leveraging innovative technologies in basic and clinical cancer researchT32CA009302 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI, Aaron M Newman · 1985 to 2026
$19.1M
Translational studies of Hsp90 inhibitors in NSCLCP50CA090578 · NCI · DANA-FARBER CANCER INST · PI JOHNSON, BRUCE D · 2008 to 2012
$11.4M
Microenvironmental control of progenitors in organ dysfunction and repairU01HL100402 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI KIM, CARLA F., SCADDEN, DAVID T · 2009 to 2015
$8.5M
Therapeutic strategies for specific subsets of KRAS mutant lung cancersR01CA140594 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WONG, KWOK KIN · 2009 to 2017
$4.5M
In vivo analysis of EGFR mutant driven lung cancers responses to radiation therapR01CA122794 · NCI · DANA-FARBER CANCER INST · PI WONG, KWOK KIN · 2006 to 2015
$2.8M
In vivo murine models of metastasis for therapeutic testingR01CA163896 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SHARPLESS, NORMAN E, WONG, KWOK KIN · 2012 to 2016
$2.0M
In Vivo and In Vitro Characterization of Bronchio-Alveolar Stem CellsR01HL090136 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI KIM, CARLA F. · 2007 to 2010
$1.9M
Howard Hughes Medical InstituteNCI NIH HHS P50 CA090578NCI NIH HHS R01 CA122794NCI NIH HHS R01 CA140594NCI NIH HHS R01 CA163896NCI NIH HHS T32 CA009302NHLBI NIH HHS R01 HL090136NHLBI NIH HHS U01 HL100402NIA NIH HHS R01 AG2400401
6 · The paper itself

Abstract

Lung cancer is notorious for its ability to metastasize, but the pathways regulating lung cancer metastasis are largely unknown. An in vitro system designed to discover factors critical for lung cancer cell migration identified brain-derived neurotrophic factor, which stimulates cell migration through activation of tropomyosin-related kinase B (TrkB; also called NTRK2). Knockdown of TrkB in human lung cancer cell lines significantly decreased their migratory and metastatic ability in vitro and in vivo. In an autochthonous lung adenocarcinoma model driven by activated oncogenic Kras and p53 loss, TrkB deficiency significantly reduced metastasis. Hypoxia-inducible factor-1 directly regulated TrkB expression, and, in turn, TrkB activated Akt signaling in metastatic lung cancer cells. Finally, TrkB expression was correlated with metastasis in patient samples, and TrkB was detected more often in tumors that did not have Kras or epidermal growth factor receptor mutations. These studies demonstrate that TrkB is an important therapeutic target in metastatic lung adenocarcinoma.

Indexed as

Cell MovementGene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticAdenocarcinomaAnimalsCell Line, TumorGene Knockdown TechniquesHumansHypoxia-Inducible Factor 1Lung NeoplasmsMembrane GlycoproteinsMice, Mutant StrainsNeoplasm MetastasisProtein-Tyrosine KinasesProto-Oncogene Proteins c-aktReceptor, trkBHypoxia-Inducible Factor 1Membrane GlycoproteinsNtrk2 protein, mouseProtein-Tyrosine KinasesProto-Oncogene Proteins c-aktReceptor, trkBNSCLCTrkB/NTRK2

Identifiers

PMID24982195
PMCPMC4104911
OpenAlexW2042736191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.